Scarica l'app Stockscreener
1.08
4.42%
-0.05
Dopo l'orario di chiusura:
1.09
0.01
+0.93%
Precedente Chiudi:
$1.13
Aprire:
$1.102
Volume 24 ore:
268.56K
Relative Volume:
2.36
Capitalizzazione di mercato:
$24.20M
Reddito:
-
Utile/perdita netta:
$-58.20M
Rapporto P/E:
-0.4149
EPS:
-2.603
Flusso di cassa netto:
$-47.21M
1 W Prestazione:
-2.70%
1M Prestazione:
-6.90%
6M Prestazione:
-10.74%
1 anno Prestazione:
-27.52%
Intervallo 1D:
$1.07
$1.115
Intervallo di 1 settimana:
$1.07
$1.165
Portata 52W:
$0.9612
$1.78
Boundless Bio Inc Stock (BOLD) Company Profile
Nome
Boundless Bio Inc
Settore
Industria
Telefono
(858) 766-9912
Indirizzo
10955 ALEXANDRIA WAY, SAN DIEGO
Compare BOLD vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.08 | 24.20M | 0 | -58.20M | -47.21M | -2.603 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-05-28 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-12-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-04-22 | Iniziato | Guggenheim | Buy |
| 2024-04-22 | Iniziato | Leerink Partners | Outperform |
| 2024-04-22 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Boundless Bio Inc Borsa (BOLD) Ultime notizie
BOLD PE Ratio & Valuation, Is BOLD Overvalued - Intellectia AI
CUE.O PE Ratio & Valuation, Is CUE.O Overvalued - Intellectia AI
LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI
APUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Recap: Will Boundless Bio Inc face regulatory challenges2026 WrapUp & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
If You Invested $1,000 in Neuphoria Therapeutics Inc (NEUP) - Stock Titan
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
What analysts say about Boundless Bio Inc stockPortfolio Gains Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, ROA, Molecules, Companies and Future Outlook - Barchart
Stop Loss: Can Boundless Bio Inc ride the EV wave2026 Gainers & Long Hold Capital Preservation Plans - baoquankhu1.vn
If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan
BOLD Technical Analysis & Stock Price Forecast - Intellectia AI
Boundless Bio: Underestimated Biotech With First-In-Class EcDNA Targeted Kinesin Degrader - Seeking Alpha
Risks Report: Is Boundless Bio Inc stock a smart retirement pick2026 Price Momentum & Technical Confirmation Trade Alerts - baoquankhu1.vn
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 - The Manila Times
Inside a novel cancer drug aiming at ecDNA-positive, high-risk breast tumors - Stock Titan
Bear Alert: Can Boundless Bio Inc ride the EV waveInsider Buying & Weekly Momentum Picks - baoquankhu1.vn
Trend Review: Can Boundless Bio Inc maintain its current growth rateWeekly Trade Recap & Weekly High Return Stock Opportunities - baoquankhu1.vn
FORTY Should I Buy - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
02386 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Gains Report: What are the analyst revisions for Boundless Bio IncIs RAAQU stock a good investment in YEARWeekly Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
ASTI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Boundless Bio posts smaller-than-expected Q4 loss - MSN
CVU Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AHRT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Leerink reiterates Market Perform on Boundless Bio stock at $4 - Investing.com
Boundless Bio Reports Q4 and Full Year 2025 Financial Results, Highlights Progress of KOMODO-1 Clinical Trial and BBI-940 Program - Minichart
03268 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
02400 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MGRD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Boundless Bio (BOLD) Posts First Revenue of $17.3M, Narrows Q4 Loss to $0.58/Share - AlphaStreet
Bold Biosciences 2025 10-K: ecDNA-Enabled Cancer Drug Development, Spyglass Platform & BBI-940 Kinesin Degrader Overview - Minichart
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Bitget
Boundless Bio beats fourth quarter loss estimates By Investing.com - Investing.com Canada
Boundless Bio 10-K: $0 Revenue, $(58.2)M Net Loss, $(63.6)M Operating Loss - TradingView
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewswire Inc.
Exit Recap: Is Boundless Bio Inc stock a smart retirement pickEarnings Summary Report & AI Enhanced Trading Signals - baoquankhu1.vn
Breakouts Watch: Can MSPRI sustain its profitabilityMarket Performance Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Boundless Bio to Participate in the Leerink Global Healthcare Conference - The Manila Times
Rezolute to Participate in the Citizens Life Sciences Conference - Bitget
Boundless Bio CEO to join Leerink healthcare fireside chat on March 11 - Stock Titan
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight – Company AnnouncementFT.com - Financial Times
BOLD Should I Buy - Intellectia AI
BOLD SEC FilingsBOUNDLESS BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
MDCX PE Ratio & Valuation, Is MDCX Overvalued - Intellectia AI
Signal Recap: How liquid is AMBIWS stock2025 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Volume Recap: Can Broadstone Net Lease Inc outperform under higher oil prices2025 Geopolitical Influence & Weekly Setup with High ROI Potential - baoquankhu1.vn
Nextech exits Boundless Bio (NASDAQ: BOLD) with reported 0% ownership - Stock Titan
Will Boundless Bio Inc. stock continue dividend increasesInflation Watch & Consistent Income Trade Recommendations - mfd.ru
What Makes CTS (CTS) a New Buy Stock - Bitget
Boundless Bio Inc Azioni (BOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):